NCT06816264View on ClinicalTrials.gov

A Study of HRS-5346 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

February 18, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions

Treatment of Lipoprotein Disorder

Interventions

DRUG

HRS-5346

HRS-5346

DRUG

Placebo

Placebo

Trial Locations (1)

100000

Peking University Third Hospital, Beijing

All Listed Sponsors

lead

Shandong Suncadia Medicine Co., Ltd.

INDUSTRY